Berbamine Ameliorates Ethanol-induced Liver Injury by Inhibition of Hepatic Inflammation in Mice
Overview
Affiliations
Alcoholic liver disease (ALD) has become one of the leading causes of death in the world. Berbamine (BM), a natural product mainly derived from Berberis vulgaris L, possesses multiple bioactivities as a traditional medicine. However, the protective effect of BM on ALD remains unknown. In this study, we investigated the effect of BM on ethanol-induced hepatic injury in mice and its underlying mechanism. It was shown that BM at 0.3125-40 μmol·Lhad no effect on macrophages and hepatocytes proliferation. BM at 5-20 μmol·L significantly inhibited lipopolysaccharide (LPS) or acetate-induced IL-1β and IL-6 mRNA expression in RAW264.7 cells. Moreover, BM treatment significantly inhibited LPS-induced p65 and STAT3 phosphorylation in RAW264.7 cells. Hepatic histopathology analysis showed that inflammatory cells infiltration and lipid accumulation were suppressed by 25 and 50 mg·kg BM administration in ethanol-induced hepatic injury mouse model. Meanwhile, BM treatment significantly inhibited serum ALT and AST levels in ethanol-fed mice. Oil red O staining results showed that BM administration ameliorated hepatic lipid accumulation in ethanol-fed mice. Preventions of ethanol-induced hepatic injury by BM were reflected by markedly decreased serum and hepatic triglyceride (TG) and total cholesterol (TC) contents. Real-time PCR results showed that BM treatment significantly inhibited pro-inflammatory cytokines mRNA expression in ethanol-fed mouse liver. Remarkably, the mechanism of action of BM was related to the reduction of ethanol-induced NF-κB and STAT3 phosphorylation levels in liver. In addition, BM treatment significantly inhibited ERK phosphorylation but not JNK and p38 of MAPK pathway. Taken together, our results demonstrate a beneficial effect of BM on ethanol-induced liver injury via a mechanism associated with inactivation of NF-κB, STAT3 and ERK pathway, which gives insight into the further evaluation of the therapeutic potential of BM for ALD.
Vitello R, Taouba H, Derand M, Liegeois J ACS Med Chem Lett. 2024; 15(2):215-220.
PMID: 38352826 PMC: 10860169. DOI: 10.1021/acsmedchemlett.3c00452.
Recent advances in anti-inflammatory active components and action mechanisms of natural medicines.
Wu Z, Zhang T, Ma X, Guo S, Zhou Q, Zahoor A Inflammopharmacology. 2023; 31(6):2901-2937.
PMID: 37947913 DOI: 10.1007/s10787-023-01369-9.
Zhang F, Wang M, Zha Y, Zhou J, Han J, Zhang S Nutrients. 2023; 15(1).
PMID: 36615880 PMC: 9823995. DOI: 10.3390/nu15010223.
Identification of a group of bisbenzylisoquinoline (BBIQ) compounds as ferroptosis inhibitors.
Fan Y, Zhang Y, Shi K, Cheng S, Pei D, Shu X Cell Death Dis. 2022; 13(11):1000.
PMID: 36435804 PMC: 9701226. DOI: 10.1038/s41419-022-05447-8.
Qi G, Jiang Z, Lu W, Li D, Chen W, Yang X Front Pharmacol. 2022; 13:1032866.
PMID: 36408260 PMC: 9666778. DOI: 10.3389/fphar.2022.1032866.